TY - JOUR
T1 - Telomere DNA Content in Prostate Biopsies Predicts Early Rise in Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer
AU - Treat, Eric G.
AU - Heaphy, Christopher M.
AU - Massie, Larry W.
AU - Bisoffi, Marco
AU - Smith, Anthony Y.
AU - Davis, Michael S.
AU - Griffith, Jeffrey K.
N1 - Funding Information:
Supported by National Institutes of Health Grant RR0164880 (to M. B. and J. K. G.), Department of Defense pre-doctoral training award W81XWH-05-0273 (to C. M. H.), University of New Mexico Cancer Center Support Grant NIH/NCI P30CA118110 , and the University of New Mexico General Clinical Research Center (NIH NCRR GCRC Grant M01-RR00997 ) (to E. G. T.).
PY - 2010/3
Y1 - 2010/3
N2 - Objective: To determine whether measurement of telomere DNA content (TC) in prostate biopsy tissue predicts prostrate-specific antigen (PSA) recurrence in men after undergoing radical prostatectomy for prostate cancer. Methods: Slot blot titration assay was used to quantitate TC in archived diagnostic prostate needle biopsy specimens for subjects (n = 103) diagnosed with prostate cancer and who subsequently underwent radical prostatectomy between 1993 and 1997. TC was compared to the clinical outcome measure; PSA recurrence, defined as an increase in PSA ≥ 0.2 ng/mL on 2 or more consecutive measurements post-prostatectomy, was observed retrospectively, for a mean follow-up period of 114 months (range, 1-165). Results: In the cohort, 46 subjects had a PSA recurrence. In a univariate Cox proportional hazards model, low TC (<0.3 of standard) demonstrated a significant risk for PSA recurrence (HR = 1.94; 95% CI: 1.02-3.69, P = .04). In a subset analysis of men with biopsy Gleason sum ≤ 6 (n = 63; 25 recurrences), a univariate Cox proportional hazards model demonstrated that low TC had a greater risk of PSA recurrence (HR = 4.53; 95% CI: 2.00-10.2, P < .01). In a multivariate Cox proportional hazards model, low TC was also significantly associated with PSA recurrence in this subset after controlling for preoperative PSA levels (HR = 6.62; 95% CI: 2.69-16.3, P < .01). Conclusions: Low TC measured in prostate biopsy tissue predicts early likelihood of post-prostatectomy PSA recurrence in a retrospective analysis, and in men with biopsy Gleason sum ≤ 6 disease it is also independent of preoperative PSA level.
AB - Objective: To determine whether measurement of telomere DNA content (TC) in prostate biopsy tissue predicts prostrate-specific antigen (PSA) recurrence in men after undergoing radical prostatectomy for prostate cancer. Methods: Slot blot titration assay was used to quantitate TC in archived diagnostic prostate needle biopsy specimens for subjects (n = 103) diagnosed with prostate cancer and who subsequently underwent radical prostatectomy between 1993 and 1997. TC was compared to the clinical outcome measure; PSA recurrence, defined as an increase in PSA ≥ 0.2 ng/mL on 2 or more consecutive measurements post-prostatectomy, was observed retrospectively, for a mean follow-up period of 114 months (range, 1-165). Results: In the cohort, 46 subjects had a PSA recurrence. In a univariate Cox proportional hazards model, low TC (<0.3 of standard) demonstrated a significant risk for PSA recurrence (HR = 1.94; 95% CI: 1.02-3.69, P = .04). In a subset analysis of men with biopsy Gleason sum ≤ 6 (n = 63; 25 recurrences), a univariate Cox proportional hazards model demonstrated that low TC had a greater risk of PSA recurrence (HR = 4.53; 95% CI: 2.00-10.2, P < .01). In a multivariate Cox proportional hazards model, low TC was also significantly associated with PSA recurrence in this subset after controlling for preoperative PSA levels (HR = 6.62; 95% CI: 2.69-16.3, P < .01). Conclusions: Low TC measured in prostate biopsy tissue predicts early likelihood of post-prostatectomy PSA recurrence in a retrospective analysis, and in men with biopsy Gleason sum ≤ 6 disease it is also independent of preoperative PSA level.
UR - http://www.scopus.com/inward/record.url?scp=77649186288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77649186288&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2009.04.032
DO - 10.1016/j.urology.2009.04.032
M3 - Article
C2 - 19615720
AN - SCOPUS:77649186288
SN - 0090-4295
VL - 75
SP - 724
EP - 729
JO - Urology
JF - Urology
IS - 3
ER -